Lupin receives USFDA’s nod for Betamethasone Dipropionate Ointment USP

20 Dec 2019 Evaluate

Lupin has received approval for its Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Diprolene Ointment, 0.05%, of Merck Sharp and Dohme Corp. The product will be manufactured at company's Pithampur Unit 3 facility, India. Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, (RLD: Diprolene) had an annual sales of approximately $ 22 million in the U.S. (IQVIA MAT September 2019).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2165.05 25.65 (1.20%)
22-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1634.40
Dr. Reddys Lab 1217.15
Cipla 1371.55
Zydus Lifesciences 884.85
Lupin 2165.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×